{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T18:30:05Z","timestamp":1777573805515,"version":"3.51.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T00:00:00Z","timestamp":1663804800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T00:00:00Z","timestamp":1663804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Merck & Co., Inc.,"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s12325-022-02303-1","type":"journal-article","created":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T10:15:07Z","timestamp":1663841707000},"page":"5259-5273","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Post-switch Effectiveness of Etanercept Biosimilar Versus Continued Etanercept in Rheumatoid Arthritis Patients with Stable Disease: A Prospective Multinational Observational Study"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1479-5302","authenticated-orcid":false,"given":"Janet","family":"Pope","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Hall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Bombardier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boulos","family":"Haraoui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graeme","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Latha","family":"Naik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol J.","family":"Etzel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dena R.","family":"Ramey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo","family":"Infante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maia","family":"Miguelez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Falcao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sevag","family":"Sahakian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,22]]},"reference":[{"issue":"5","key":"2303_CR1","doi-asserted-by":"publisher","first-page":"669","DOI":"10.3899\/jrheum.200367","volume":"48","author":"KB Almutairi","year":"2021","unstructured":"Almutairi KB, Nossent JC, Preen DB, Keen HI, Inderjeeth CA. The prevalence of rheumatoid arthritis: a systematic review of population-based studies. J Rheumatol. 2021;48(5):669\u201376.","journal-title":"J Rheumatol"},{"issue":"4","key":"2303_CR2","doi-asserted-by":"publisher","first-page":"880","DOI":"10.3390\/cells9040880","volume":"9","author":"YJ Lin","year":"2020","unstructured":"Lin YJ, Anzaghe M, Sch\u00fclke S. Update on the pathomechanism, diagnosis, and treatment options for rheumatoid arthritis. Cells. 2020;9(4):880.","journal-title":"Cells"},{"issue":"3","key":"2303_CR3","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.autrev.2004.09.002","volume":"4","author":"Y Alamanos","year":"2005","unstructured":"Alamanos Y, Drosos AA. Epidemiology of adult rheumatoid arthritis. Autoimmun Rev. 2005;4(3):130\u20136.","journal-title":"Autoimmun Rev"},{"key":"2303_CR4","first-page":"3","volume":"4","author":"R Fleischmann","year":"2011","unstructured":"Fleischmann R, Wells AF, Kavanaugh A. New biologic agents in patients with rheumatoid arthritis. Update Rheum Dis Clin N A. 2011;4:3\u201320.","journal-title":"Update Rheum Dis Clin N A"},{"issue":"1","key":"2303_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/acr.22783","volume":"68","author":"JA Singh","year":"2016","unstructured":"Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2016;68(1):1\u201325.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4 Suppl 73","key":"2303_CR6","first-page":"S102","volume":"30","author":"G Lapadula","year":"2012","unstructured":"Lapadula G, Ferraccioli GF. Biosimilars in rheumatology: pharmacological and pharmacoeconomic issues. Clin Exp Rheumatol. 2012;30(4 Suppl 73):S102\u20136.","journal-title":"Clin Exp Rheumatol"},{"key":"2303_CR7","doi-asserted-by":"publisher","first-page":"4063","DOI":"10.1093\/rheumatology\/keaa877","volume":"60","author":"X Yue","year":"2021","unstructured":"Yue X, Huang B, Hincapie AL, et al. Comparative effectiveness and persistence of TNFi and non-TNFi in juvenile idiopathic arthritis: a large paediatric rheumatology centre in the USA. Rheumatology (Oxford). 2021;60:4063\u201373.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"2303_CR8","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1136\/annrheumdis-2020-217209","volume":"80","author":"DA Pappas","year":"2021","unstructured":"Pappas DA, St John G, Etzel CJ, et al. Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study. Ann Rheum Dis. 2021;80(1):96\u2013102.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"2303_CR9","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s12325-018-0757-2","volume":"35","author":"P Emery","year":"2018","unstructured":"Emery P, Pope JE, Kruger K, et al. Efficacy of monotherapy with biologics and JAK inhibitors for the treatment of rheumatoid arthritis: a systematic review. Adv Ther. 2018;35(10):1535\u201363.","journal-title":"Adv Ther"},{"key":"2303_CR10","unstructured":"U.S. Food and Drug Administration. Guidance for industry: clinical pharmacology data to support a demonstration of biosimilarity to a reference product. 2014. https:\/\/www.biosimilarslawblog.com\/files\/2014\/10\/Draft_Guidance_for_Industry_on_Clinical_Pharmacology_Data_to_Support_a_Demonstration_of_Biosimilarity_to_a_Reference_Product-1.pdf. Accessed 18 Jan 2022."},{"issue":"3","key":"2303_CR11","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.rdc.2019.04.001","volume":"45","author":"J Kay","year":"2019","unstructured":"Kay J. Are there benefits and risks to biosimilars from a patient perspective? Rheum Dis Clin N Am. 2019;45(3):465\u201376.","journal-title":"Rheum Dis Clin N Am"},{"issue":"2","key":"2303_CR12","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s40265-020-01256-5","volume":"80","author":"H Kim","year":"2020","unstructured":"Kim H, Alten R, Avedano L, et al. The future of biosimilars: maximizing benefits across immune-mediated inflammatory diseases [published correction appears in Drugs. 2020;80(10):1039-1040]. Drugs. 2020;80(2):99\u2013113.","journal-title":"Drugs"},{"key":"2303_CR13","doi-asserted-by":"crossref","unstructured":"Takeuchi T, Nishikawa K, Yamada F, et al. Real-world safety and efficacy of CT-P13, an infliximab biosimilar, in Japanese rheumatoid arthritis patients na\u00efve to or switched from biologics. Mod Rheumatol. 2021;32(4):718\u201327.","DOI":"10.1093\/mr\/roab068"},{"issue":"2","key":"2303_CR14","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1136\/annrheumdis-2018-213474","volume":"78","author":"B Glintborg","year":"2019","unstructured":"Glintborg B, Loft AG, Omerovic E, et al. To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry. Ann Rheum Dis. 2019;78(2):192\u2013200.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"2303_CR15","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40744-019-00169-4","volume":"6","author":"HC Ebbers","year":"2019","unstructured":"Ebbers HC, Pieper B, Issa A, Addison J, Freudensprung U, Rezk MF. Real-world evidence on etanercept biosimilar SB4 in etanercept-na\u00efve or switching patients: a systematic review. Rheumatol Ther. 2019;6(3):317\u201338.","journal-title":"Rheumatol Ther"},{"issue":"12","key":"2303_CR16","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1136\/annrheumdis-2017-211591","volume":"76","author":"P Emery","year":"2017","unstructured":"Emery P, Vencovsk\u00fd J, Sylwestrzak A, et al. Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4. Ann Rheum Dis. 2017;76(12):1986\u201391.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"2303_CR17","doi-asserted-by":"publisher","first-page":"621","DOI":"10.3390\/jcm11030621","volume":"11","author":"S Parisi","year":"2022","unstructured":"Parisi S, Becciolini A, Ditto MC, et al. Efficacy and drug survival after switching from etanercept to the biosimilar SB4: a real-life long-term study. J Clin Med. 2022;11(3):621.","journal-title":"J Clin Med"},{"key":"2303_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.biologicals.2019.10.009","volume":"62","author":"C Codreanu","year":"2019","unstructured":"Codreanu C, Popescu CC, Mogo\u015fan C, et al. Efficacy and safety of original and biosimilar etanercept (SB4) in active rheumatoid arthritis\u2014a comparison in a real-world national cohort. Biologicals. 2019;62:27\u201332.","journal-title":"Biologicals"},{"issue":"2","key":"2303_CR19","doi-asserted-by":"publisher","first-page":"365","DOI":"10.55563\/clinexprheumatol\/usrd9z","volume":"39","author":"C Selmi","year":"2021","unstructured":"Selmi C, Kr\u00fcger K, Cantagrel A, et al. BENEFIT: real-world effectiveness of SB4 after transition from reference etanercept in rheumatoid arthritis and axial spondyloarthritis. Clin Exp Rheumatol. 2021;39(2):365\u201371.","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"2303_CR20","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00228-020-02957-2","volume":"77","author":"O Al Tabaa","year":"2021","unstructured":"Al Tabaa O, Etcheto A, Dumas S, et al. Doctor\u2019s aptitude for switching from innovator etanercept to biosimilar etanercept in inflammatory rheumatic diseases: experience from a single French rheumatology tertiary care center. Eur J Clin Pharmacol. 2021;77(1):25\u201333.","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"2303_CR21","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.semarthrit.2018.07.005","volume":"48","author":"M Scherlinger","year":"2019","unstructured":"Scherlinger M, Langlois E, Germain V, Schaeverbeke T. Acceptance rate and sociological factors involved in the switch from originator to biosimilar etanercept (SB4). Semin Arthritis Rheum. 2019;48(5):927\u201332.","journal-title":"Semin Arthritis Rheum"},{"key":"2303_CR22","doi-asserted-by":"publisher","first-page":"1759720X2096403","DOI":"10.1177\/1759720X20964031","volume":"12","author":"C Bruni","year":"2020","unstructured":"Bruni C, Gentileschi S, Pacini G, et al. The switch from etanercept originator to SB4: data from a real-life experience on tolerability and persistence on treatment in joint inflammatory diseases. Ther Adv Musculoskelet Dis. 2020;12:1759720X20964031.","journal-title":"Ther Adv Musculoskelet Dis"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02303-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-022-02303-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02303-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T15:51:09Z","timestamp":1664553069000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-022-02303-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,22]]},"references-count":22,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["2303"],"URL":"https:\/\/doi.org\/10.1007\/s12325-022-02303-1","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,22]]},"assertion":[{"value":"2 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}